Judges Scientific Share Price: Is JDG a Buy Now

If you’ve been scanning the AIM for a steady compounder, Judges Scientific (LSE:JDG) rarely pops up in headlines — but it has quietly built a portfolio of niche instrument makers that’s drawn a Strong Buy consensus from analysts. With the share price sitting at 4,400p and a forecast target suggesting nearly 37% upside, the question isn’t just about price — it’s about whether the acquisition playbook still works.

Current Price: 4,400p ·
Previous Close: 4,400p ·
Open Price: 4,425p ·
Volume: 17,383 ·
Turnover: £390,937.30 ·
Buy/Sell Spread: 4,500p / 4,400p

Seven snapshots from the trading screen, each telling a part of the story.

Is Judges Scientific a good buy?

Current analyst ratings and price targets

Four analysts covering JDG on Investing.com (broker consensus aggregator) assign a consensus of Strong Buy — 3 Buy, 1 Hold, 0 Sell. The average 12-month price target sits at 6,450p, with a high of 7,200p and a low of 6,000p. Stockopedia also rates it Strong Buy and reports a consensus target of 6,450p, implying 37.23% upside from the last close of 4,700p.

• Mean target: 6,450p (MarketScreener (equity research aggregator) shows 87.56 GBP average, but pence figures differ — likely due to data lag)
• High target: 7,200p (Investing.com)
• Low target: 6,000p (Investing.com)

Key financial ratios for valuation

According to Hargreaves Lansdown (UK broker platform), Judges Scientific trades at a trailing P/E of 15.98 and offers a dividend yield of 2.61%. The market capitalisation stands at £293.06 million. For context, the broader AIM Industrial index trades at a median P/E of 18-20, so JDG sits slightly below sector average on earnings multiple.

These ratios frame the current valuation and highlight a potential entry point for value-focused investors.

Recent share price performance

The stock last closed at 4,700p, then opened at 4,425p on May 29, settling at 4,400p. Over the past 12 months, the price has fallen 42.82% (Stockopedia). However, year-to-date it has recovered about 8% from its lows.

What is the fair value of Judges Scientific?

Discounted cash flow (DCF) approach

Simply Wall St (independent valuation tool) estimates fair value at UK£68.38 per share based on a DCF model. That equates to roughly 6,838p — implying the current price of 4,400p trades at a 36% discount. However, the model assumes revenue growth that they forecast to decline by 0.9% per annum, while earnings are expected to grow at 41.6% annually — a divergence that raises questions about margin assumptions.

Comparable company analysis

Using peer multiples, MarketScreener reports an average target of 87.56 GBP (8,756p) with a high of 100.00 GBP and low of 73.80 GBP. These figures are from a snapshot dated mid-2025, so may be stale. Still, they suggest a fair value range of 7,380p – 10,000p before adjusting for the recent share price decline.

Book value and earnings multiples

At a P/E of 15.98x trailing earnings, JDG trades below the AIM industrial average. If earnings grow at the forecast 16% per annum, the forward P/E drops to approximately 12x — historically cheap for a niche technology holding company.

How does Judges Scientific make money?

Acquisition strategy and operational model

Judges Scientific is a holding company that buys small, profitable scientific instrument makers — think niche labs, testing equipment, and measurement devices. The model: acquire, keep management, provide central support, and let them grow. This “buy-and-build” approach has steadily expanded the portfolio without taking on excessive debt.

Revenue breakdown by acquired subsidiaries

The group’s revenue comes entirely from its operating subsidiaries. According to the company’s latest annual report (available on the official website), revenue grew 15% in the last fiscal year. The company does not publish segment breakdowns by subsidiary, but the mix spans from tensile testers to environmental chambers.

Profitability and margins

Gross margins typically run above 50% for scientific instruments. Operating margins are moderate due to the holding company structure. Simply Wall St forecasts return on equity to reach 17.2% in three years, implying improving capital efficiency.

Is Judges Scientific’s stock a good investment?

Long-term performance and volatility

Over the last five years, the stock has shown steady appreciation before the recent drawdown. The 12-month drop of 42.82% (Stockopedia) is sharp, but the long-term trend is upward. For context, the AIM index fell roughly 10% over the same period, so JDG has underperformed significantly recently.

Dividend history and stability

Hargreaves Lansdown reports a consistent dividend yield of 2.61%. The company has paid dividends without interruption for at least the last five years.

Risk factors and sector exposure

Key risks: integration of new acquisitions, cyclicality in capital equipment spending, and low trading liquidity (volume of 17,383 shares today). The niche focus reduces exposure to broad economic swings but concentrates risk in the scientific instruments sector.

What is the forecast for Judges Scientific share price?

Analyst price targets and consensus

Based on four analyst projections, the average 12-month target is 6,450p (Investing.com). Stockopedia reports the same average target of 6,450p, implying 37.23% upside from the last close of 4,700p. The high estimate is 7,200p, the low is 6,000p.

Historical price patterns and trends

Technical analysis shows support around 4,200p (the area that held during the 2022 selloff) and resistance near 4,600p (the current 50-day moving average). A break above 4,600p could open the path toward 5,000p and then the analyst targets.

Macroeconomic and sector influences

Interest rates and government R&D spending directly affect scientific instrument demand. The UK’s R&D tax credit regime is a tailwind. A recession could delay capital purchases, but the niche nature of JDG’s instruments (often essential for compliance testing) provides some buffer.

Five key specifications that define the stock’s investment profile.

“Overall consensus recommendation for Judges Scientific is Strong Buy.”

— Stockopedia (financial data platform) as of May 2026

“Projections from 4 analysts give Judges Scientific an average 12-month price target of 6,450.0 GBP.”

— Investing.com (analyst consensus aggregator) as of late May 2026

“Judges Scientific has a P/E ratio of 15.98 and a dividend yield of 2.61%.”

— Hargreaves Lansdown (UK retail broker) as of market close May 28

“Judges Scientific’s fair value is estimated at UK£68.38 per share based on a DCF model.”

— Simply Wall St (independent equity research) as of last model update

For UK investors considering a position in AIM-listed scientific instruments, the choice is clear: the stock offers a 37% target upside and a 2.61% yield, but the 42% one-year decline signals real execution risk. If the acquisition pipeline delivers, JDG could reward patient holders. If deals stall, the discount to fair value may widen further. Investors should decide based on their own time horizon and risk appetite.